Verrica Pharmaceuticals Forecasts Narrower Q1 Loss, Strong Revenue Growth
VRCA has more than doubled off its 52-week low of $3.28.
Summary
Analysts anticipate Verrica Pharmaceuticals will report a Q1 loss of 38 cents per share, a notable improvement compared to recent actual losses, alongside a projected 32.1% increase in revenue to $4.52 million. This earnings preview is significant for a company that recently disclosed a 'going concern' warning in its last 10-K. The improved loss expectation and robust revenue growth could indicate a positive operational trajectory, potentially easing some investor concerns regarding its financial stability. Traders will be watching the actual Q1 results on May 12 closely to confirm if these improved expectations are met or exceeded.
At the time of this announcement, VRCA was trading at $7.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $137.3M. The 52-week trading range was $3.28 to $9.82. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.